NCT05748925View on ClinicalTrials.gov

Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2024

Conditions
SLELupus NephritisSGLT2 Inhibitors
Interventions
DRUG

dapagliflozin

The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.

DRUG

placebo

Control group: will be maintained on their medication

Trial Locations (1)

35511

Urology and Nephrology Center, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER